Evogene Q2 Loss Narrows to $1.8M; Cash Burn Cut to $8.5–$9.5M
EVGN sits 62% above its 52-week low of $0.37 on light trading volume (0.2× avg).
Summary
Evogene reported a narrower Q2 net loss of $1.8M and cut 2026 cash burn guidance to $8.5–$9.5M, backed by $9.3M in cash and six drug discovery collaborations.
Key Events · Earnings and Guidance · EVGN
-
Q2 Net Loss Narrows to $1.8M
Net loss for Q2 2026 was $1.8M, down from $4.7M in Q2 2025, driven by lower operating expenses and reduced losses from discontinued operations.
-
Cash Burn Guidance Cut to $8.5–$9.5M
Full-year 2026 cash usage is expected to be $8.5–$9.5M, down from $14.4M in 2025 and $20.5M in 2024, with further reductions targeted for 2027.
-
Cash Position of $9.3M
Consolidated cash and cash equivalents were $9.3M as of June 30, 2026, with Q2 cash usage of approximately $2.1M.
-
Six Active Drug Collaborations
Evogene has six active drug development collaborations with biotech companies and academic institutions, with two programs completing initial Hit Identification with validation results exceeding partner expectations.
Analysis · EVGN · Industrial Applications And Services
A sharply reduced net loss of $1.8 million versus $4.7 million a year ago underscores the impact of aggressive cost cuts that shrank the workforce from 117 to 38 employees. Full-year cash burn is now expected at $8.5–$9.5 million, down from $14.4 million in 2025, extending the runway with $9.3 million in cash. Six active drug discovery collaborations and a 300% expansion of the AI chemical library to 110 billion molecules offer early commercial validation, yet revenue remains minimal at $0.3 million for the quarter. These results land amid an ongoing activist proxy fight and a highly dilutive ATM program, making the improved cash efficiency a critical survival signal.
At the time of this filing, EVGN was trading at $0.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.